Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive lanicemine in treatment-resistant major depressive disorder
2011-004690-87Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lanicemine in major depressive disorder (MDD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Primary efficacy endpoint. Started Apr 2012; status: completed.
02
Drugs
lanicemine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-004690-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004690-87.